Search
Close this search box.

Preparing for the Future: A Gene Therapy Vector Production Platform

This project will develop a scalable platform process for production, purification, and analysis of adeno-associated virus (AAV) vectors used in gene therapy.
Categories
Cell and Gene therapies
Drug substance
Assays
Incumbent worker training
Project status
100% Completed

Solution

Performance Period: 4/15/2018 to 6/30/2019

The emergence of commercial gene therapy products will require a transition from bench-scale production of gene therapy vectors to manufacturing-scale operations. This project will develop a scalable platform process for production, purification, and analysis of adeno-associated virus (AAV) vectors used in gene therapy. This resource will be available for use throughout the NIIMBL network, and enable:

  • development of hands-on courses in the area of gene therapy vector production; and,
  • development and testing of new process and analytical technologies for vector production. 

In addition to these broad project goals, the following specific objectives will be met:

  • Develop and offer a hands-on short course in gene therapy vector manufacturing that would be offered to NIIMBL members and the broader biopharmaceutical community.
  • Test Sudhin Biopharma’s inclined settler technology for separation of cells and cell debris from liquid streams in the vector production process.

Updates, Related Publications, and Deliverables

  • Login to the NIIMBL member portal for access to project updates, related publications, and deliverables. 

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

North Carolina State University

North Carolina State University

Participating Organizations

Sudhin Biopharma Co

Sudhin Biopharma Co

University of North Carolina, Chapel Hill

University of North Carolina, Chapel Hill

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?